SAN FRANCISCO — The J.P. Morgan Healthcare Conference, a massive conference attended by thousands of pharmaceutical industry executives, investors, bankers, and analysts, is off and running in San Francisco’s Union Square.
Walking through the halls of the hotels that house the main events, a few topics seem to be on the tops of everyone’s minds.
From new arrivals heading up big biotech and pharmaceutical companies, to doubts about 2019’s first mega-merger, here’s what Business Insider’s healthcare team is hearing at the conference.
What’s a mega-merger to do?
Walking from meeting to meeting, it’s hard not to hear chatter about the $74 billion Bristol-Myers Squibb-Celgene deal.
The deal, announced last week, combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in the development of cancer drugs.
But among attendees of the conference, there’s some skepticism about whether the deal will go through. Instead, there’s a possibility that another pharmaceutical company could come in and make a bid for BMS — nixing its deal with Celgene entirely.
The big tech elephant in the room
Rumors that Amazon and Apple employees are attending the conference have healthcare veterans wondering what that might mean for the two giants’ health strategy.
While some initiatives Amazon’s working on — like the PillPack acquisition and the joint healthcare venture with JPMorgan and Berkshire Hathaway — have clicked into place, there’s still a lot we don’t know about Amazon’s healthcare strategy. That should have the healthcare industry worried.
While retail pharmacy giants seem to be setting up delivery services that could protect them from Amazon, it remains to be seen if drugmakers or other parts of healthcare will need to find new ways to be competitive or find ways to partner up with Amazon instead.
A number of pharma and biotech companies had new presenters up on stage. New CEOs heading up Pfizer and Gilead drew a lot of curiosity over where they’d take the companies.
And Moderna, the biggest biotech initial public offering in history made its first presentation at the conference as a publicly traded company to an overflowing room of spectators.
And then there’s newly formed companies like CVS Health, which in 2018 finalized its merger with Aetna. In its presentation, CVS laid out how it plans to incorporate the health plan into its retail pharmacy business to create home hubs. CVS’s presentation was overflowing, too.
Lisa Gill, the JPMorgan analyst who covers the company, joked at the start: “Just as a side note, I think we’re going to have to move you back to the big room next year.”
We’ll be sending out our best stories from the week in Dispensed, our weekly dispatch of pharma, biotech, and healthcare news. Sign up here.
- Read more:
- A biotech is proposing a plan to pay for its pricey rare disease treatment the same way you’d buy a TV or dishwasher. Here’s the inside story
- CVS Health just revealed a key piece of its plan to change how Americans get healthcare
- A Silicon Valley startup that pioneered a new way to fight diabetes is tackling depression after its CEO noticed a disturbing trend
- 250 more hospitals just joined in on a plan to make their own drugs and the effort could upend the generic pharma business